David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols | EP #249
In this live-event conversation, Peter Diamandis and Harvard longevity researcher David Sinclair discuss the imminent first human trial of Sinclair-lab-derived OSK epigenetic reprogramming gene therapy (targeting blindness), the broader push toward a cheaper small-molecule version of the same technology, and whether there is any hard ceiling on human lifespan. Sinclair argues no biological law mandates aging and floats the idea that 2026 could be the year age reversal is proven possible in humans. The two also cover Friends of Sinclair Lab, a philanthropic funding vehicle Diamandis's Moonshots community launched after Sinclair's federal research funding was cut, and Sinclair's personal longevity protocol (resveratrol, NMN, metformin/berberine, nattokinase, diet, alcohol, and stress management).
First human epigenetic reprogramming trial (OSK gene therapy)Longevity▶ 2:01
Life Biosciences is about to begin the first human trial of Sinclair-lab-derived OSK gene therapy, injecting it into the eye to attempt to cure blindness, after success in mice and monkeys.
Sinclair recounts how his student found that only 3 of the 4 Yamanaka reprogramming genes (OSK) could reverse aging safely, since using all 4 kills mice within days.
Expanding reprogramming to other organs and diseasesLongevity▶ 4:00
Sinclair lists organs and conditions where his lab and others have seen reprogramming benefits in mice, including brain, memory/Alzheimer's, ALS/motor neurons, immune system, muscle, kidney, liver, skin, and joints/cartilage, arguing a true longevity therapeutic must work body-wide.
Cost and delivery: from expensive gene therapy to cheap pillBiotech▶ 6:28
Current AAV-based OSK gene therapy costs hundreds of thousands to millions per treatment; Sinclair's lab has worked since 2017 on a small-molecule alternative that could eventually cost only cents per pill, using AI to screen billions of candidate molecules.
Small-molecule reprogramming cocktail and Xprize trialLongevity▶ 9:16
Sinclair has a proof-of-concept small-molecule cocktail that reverses cellular aging and plans to move it into a human clinical trial within months as part of the Healthspan Xprize.
Is there an upper limit to human lifespan?Longevity▶ 14:59
Sinclair argues no biological law requires aging, that the current human max (122 years) is not a ceiling, and that new reprogramming science suggests lifespans of hundreds or even thousands of years may eventually be achievable, though he stops short of promising immortality.
Cellular reprogramming as a 'reboot' rather than just rejuvenationBiotech▶ 16:17
Sinclair distinguishes his current work, literally resetting a cell's epigenetic age so it 'is young and stays young,' from his lab's earlier 20 years of work that only made old cells behave younger, and notes mice have been safely reprogrammed multiple times.
Friends of Sinclair Lab (FOSL): philanthropic funding after a federal funding cutEconomy▶ 17:48
After Sinclair's lab lost roughly $2-3 million a year in federal funding amid a Harvard/White House dispute, Diamandis and the Moonshots audience launched Friends of Sinclair Lab, raising about $6 million in private annual support and enabling project funding within weeks instead of years.
Critique of the traditional science grant systemEconomy▶ 19:46
Sinclair and Diamandis argue conventional grant funding punishes radical ideas, is slow and reactive, wastes scientists' time on grant-writing, and gives only about a 10% funding success rate, contrasted with FOSL's rapid, direct funding model.
David Sinclair's personal longevity supplement protocolHealth▶ 24:03
Sinclair details his 15+ year regimen of resveratrol (taken with fat/protein for absorption), NMN, and a glucose-lowering drug (metformin or berberine), plus a newly disclosed link between sirtuins and reprogramming.
Nattokinase and cardiovascular monitoringHealth▶ 27:38
Sinclair discusses nattokinase as the only supplement he knows of clearly shown in large trials to reverse arterial plaque (at roughly 10,000 units/day over a year), and prefers ultrasound carotid scans over CT scans to avoid aging-accelerating radiation.
Sinclair describes going mostly vegan and quitting daily alcohol, citing data linking even one drink a day to smaller brain volume, and credits his partner Serena with teaching him to manage the chronic stress and perfectionism he believes accelerates aging.
Predictions made
openDavid Sinclair: Age-reversal pills based on this reprogramming technology will become available within our lifetime.
EP #? · · due: within Sinclair's lifetime (unspecified decades) · ▶ watch
“I can see a future where, certainly within our lifetime, we'll have these pills available.”
Your call:
openDavid Sinclair: 2026 may be the year humanity learns that age reversal is possible in humans.
“It may be sooner than we think. It may be 2026 is the year we learn that age reversal is possible in humans.”
Your call:
openDavid Sinclair: Doctors may know within about 6 weeks of dosing whether the ER100 eye gene therapy works in humans.
EP #? · · due: 6 weeks after trial dosing begins · ▶ watch
“You only need 6 weeks. So, in 6 weeks, some doctor may even know the answer whether this works in humans.”
Your call:
openDavid Sinclair: His small-molecule age-reversal cocktail will enter a human clinical trial within a couple of months, as part of the Healthspan Xprize.
EP #? · · due: within a couple of months of April 2026 · ▶ watch
“Those we hope to put into a clinical trial into humans within the next couple of months as part of our Xprize competition.”
Your call:
openDavid Sinclair: The eventual longevity small-molecule drug will become as cheap and widely accessible as metformin, potentially costing only cents per pill.
“You predicted a couple hundred bucks a month as a potential range.”
Your call:
openDavid Sinclair: Humans may eventually be able to live for hundreds, possibly thousands, of years.
EP #? · · due: unspecified, very long term · ▶ watch
“It feels weird to say we can live hundreds of years, maybe thousands of years.”
Your call:
openDavid Sinclair: As more safety data accumulates, reprogramming therapy will eventually be deliverable intravenously as a whole-body treatment rather than tissue by tissue.
EP #? · · due: unspecified, contingent on new delivery technology · ▶ watch
“I don't see a reason why, as we learn more and we see more safety, that we couldn't go, you know, intravenously.”
Your call:
Numbers that matter
2020Year Sinclair lab's OSK reprogramming paper was published on the cover of Nature magazine under the title 'Turning Back Time.'
2 daysMice die within 2 days if given the full set of Yamanaka reprogramming genes, which is why Sinclair's lab uses only 3 of them (OSK).
$500,000 to $2,000,000Typical historical cost per treatment for AAV gene therapies, per Diamandis.
2017Year Sinclair's lab developed the OSK gene-therapy technology now entering human trials.
6 weeksDosing and observation window for the ER100 eye gene therapy trial before efficacy may become apparent.
92 years oldAge of human donor skin cells being tested in the lab to see if AI-selected molecules can reverse them toward a 20-year-old state.
3 moleculesNumber of molecules in the current age-reversal cocktail; Sinclair intends to reduce this to one molecule for market.
hundreds of thousands of dollarsCurrent manufacturing cost of the three-factor molecule cocktail at kilogram scale.
a couple hundred dollars a monthSinclair's previously stated potential price target for the eventual longevity pill.
122 yearsLongest verified human lifespan on record, cited as the current maximum Sinclair believes can be surpassed.
$2 to $3 million per yearApproximate federal funding Sinclair's lab lost due to the Harvard/White House funding dispute.
$6 millionPrivate annual support raised for Sinclair's lab through Friends of Sinclair Lab after the government funding cut.
$50,000Entry contribution level for Friends of Sinclair Lab; Diamandis contributed the first $50K to launch it.
$1 millionAmount some Friends of Sinclair Lab members have contributed.
70 membersCurrent size of the Friends of Sinclair Lab community, intentionally capped to preserve its close-knit feel.
Worth digging into
🕳️ AI-driven small-molecule replacement for OSK gene therapy
Could collapse treatment cost from $500K-$2M gene therapy down to a cents-per-pill drug, with a proof-of-concept cocktail already tested in animals.
🕳️ Friends of Sinclair Lab philanthropic funding model
A novel bypass of the traditional NIH-style grant system that raised roughly $6M/year in private funding and enables project funding in weeks instead of years.
🕳️ 2026 as a potential proof point for human age reversal
Sinclair floats 2026 as the year age reversal could be shown possible in humans, tied to the OSK eye trial's roughly 6-week readout window.
🕳️ Sirtuins as the mechanistic link to epigenetic reprogramming
Sinclair disclosed for the first time publicly that sirtuins (his original research focus for 20+ years) are important for OSK reprogramming, potentially unifying his life's two major research threads.
🕳️ Nattokinase's plaque-reversal claim
Presented as the only supplement with large-trial evidence (1,000+ people) for reversing arterial plaque, with a specific effective dose (10,000 units/day for a year) and a null result at a lower dose.